AdvanSix Valuation

Is 960 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 960 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 960 (€29.6) is trading below our estimate of fair value (€210.87)

Significantly Below Fair Value: 960 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 960?

Key metric: As 960 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 960. This is calculated by dividing 960's market cap by their current earnings.
What is 960's PE Ratio?
PE Ratio21.7x
EarningsUS$38.72m
Market CapUS$841.49m

Price to Earnings Ratio vs Peers

How does 960's PE Ratio compare to its peers?

The above table shows the PE ratio for 960 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.5x
SIM0 SIMONA
10.8xn/a€336.0m
FPE3 Fuchs
19x8.6%€5.0b
ACT AlzChem Group
12.2x12.8%€612.6m
SDF K+S
79.9x57.4%€2.0b
960 AdvanSix
21.7x105.5%€841.5m

Price-To-Earnings vs Peers: 960 is good value based on its Price-To-Earnings Ratio (21.7x) compared to the peer average (30.5x).


Price to Earnings Ratio vs Industry

How does 960's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
960 21.7xIndustry Avg. 17.5xNo. of Companies11PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 960 is expensive based on its Price-To-Earnings Ratio (21.7x) compared to the European Chemicals industry average (17.5x).


Price to Earnings Ratio vs Fair Ratio

What is 960's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

960 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.7x
Fair PE Ratio78.2x

Price-To-Earnings vs Fair Ratio: 960 is good value based on its Price-To-Earnings Ratio (21.7x) compared to the estimated Fair Price-To-Earnings Ratio (78.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 960 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€29.60
€36.01
+21.7%
4.0%€37.45€34.57n/a2
Dec ’25€29.60
€36.01
+21.7%
4.0%€37.45€34.57n/a2
Nov ’25€25.80
€32.51
+26.0%
1.4%€32.97€32.06n/a2
Oct ’25€26.80
€32.51
+21.3%
1.4%€32.97€32.06n/a2
Sep ’25€26.60
€32.51
+22.2%
1.4%€32.97€32.06n/a2
Aug ’25€25.60
€31.67
+23.7%
5.9%€33.53€29.80n/a2
Jul ’25€21.00
€31.67
+50.8%
5.9%€33.53€29.80n/a2
Jun ’25€21.20
€34.36
+62.1%
12.3%€39.93€29.72n/a3
May ’25€24.40
€36.01
+47.6%
8.6%€40.40€33.82n/a3
Apr ’25€25.20
€34.17
+35.6%
5.1%€36.62€32.95n/a3
Mar ’25€25.60
€34.45
+34.6%
5.1%€36.91€33.22n/a3
Feb ’25€23.20
€35.49
+53.0%
6.5%€38.55€33.04n/a3
Jan ’25€27.40
€37.27
+36.0%
12.9%€43.99€32.99n/a3
Dec ’24€23.60
€37.27
+57.9%
12.9%€43.99€32.99€29.603
Nov ’24€25.60
€44.28
+73.0%
15.4%€53.71€37.69€25.803
Oct ’24€28.80
€47.38
+64.5%
7.5%€52.27€44.02€26.803
Sep ’24€30.20
€47.38
+56.9%
7.5%€52.27€44.02€26.603
Aug ’24€36.00
€46.89
+30.2%
5.8%€50.57€44.13€25.603
Jul ’24€32.00
€46.89
+46.5%
5.8%€50.57€44.13€21.003
Jun ’24€30.40
€46.89
+54.2%
5.8%€50.57€44.13€21.203
May ’24€33.20
€49.18
+48.1%
5.3%€52.23€45.82€24.403
Apr ’24€34.00
€51.34
+51.0%
9.6%€58.22€46.96€25.203
Mar ’24€38.20
€51.34
+34.4%
9.6%€58.22€46.96€25.603
Feb ’24€39.20
€51.01
+30.1%
8.5%€57.16€47.94€23.203
Jan ’24€35.40
€56.94
+60.9%
15.4%€69.31€50.76€27.403
Dec ’23€39.00
€56.94
+46.0%
15.4%€69.31€50.76€23.603

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies